These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 10395117

  • 1. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
    Dulaney Lopez AM, Rodriguez JC, Lopez-Samblas AM, Estes KS.
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF, Bulitta J, Lipman J, Kirkpatrick CM.
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Modeling and simulation of intravenous levetiracetam pharmacokinetic profiles in children to evaluate dose adaptation rules.
    Snoeck E, Jacqmin P, Sargentini-Maier ML, Stockis A.
    Epilepsy Res; 2007 Sep; 76(2-3):140-7. PubMed ID: 17851036
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients.
    Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, Bruining HA.
    J Antimicrob Chemother; 2004 Jul; 54(1):199-205. PubMed ID: 15175266
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic options for cefotaxime in the management of bacterial infections.
    Raddatz JK, Ostergaard BE, Rotschafer JC.
    Diagn Microbiol Infect Dis; 1995 Jun; 22(1-2):77-83. PubMed ID: 7587054
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P, Hurd DD, Salfi M, Cheah TC, Aycock J, Cesano A.
    Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
    Béranger A, Oualha M, Urien S, Genuini M, Renolleau S, Aboura R, Hirt D, Heilbronner C, Toubiana J, Tréluyer JM, Benaboud S.
    Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.